INTRODUCTION

Top Abstract Introduction Materials and Methods Results Discussion References

Human papillomaviruses (HPVs), a group of small icosahedral viruses with circular 8-kb DNA, have a strong epithelial tropism (57). To date more than 80 HPV genotypes have been identified and classified on the basis of their pathogenicity and target tissues. HPVs that infect the cutaneous epithelium, such as types 1, 2, 4, and 8, mainly cause skin warts. HPVs that infect the mucosal epithelium, such as types 6 and 11, cause benign condyloma, but types 16, 18, 31, and 33 cause cervical cancer (35, 58). All HPVs have overall similarity in genomic organization; the early region encoding the nonstructural viral proteins (E1 through E7 proteins), the late region encoding the two capsid proteins (L1 and L2 proteins), and the noncoding regulatory region (long control region [LCR]) between the L1 and E6 genes (57).

HPVs that infect basal cells of the epithelium through microlesions are known to express their genes in such a way as to be tightly linked to the differentiation state of the host cells (34). The differentiation-dependent viral transcription has been studied mainly in immortalized human keratinocytes harboring HPV16 (15, 18, 29) or HPV31 (7, 25, 37). In undifferentiated cells the promoter in the LCR, such as HPV16 P₉₇ or HPV31 P₉₇, is active and directs transcription of E6, E7, and some other early genes, but the promoter in the E7 open reading frame (ORF), such as HPV16 P₆₇₀ or HPV31 P₇₄₂, is suppressed (18, 25, 38). Differentiation of the host cells induces a dramatic increase of transcriptional activities of P₆₇₀ and P₇₄₂, resulting in expression of E1 and its downstream late genes (18, 21, 25, 31, 38, 45). Recently, the promoter in the HPV6 E7 ORF has been shown to be negatively regulated by CCAAT displacement protein (CDP) (2) and YY1, a multifunctional protein acting as a transcriptional activator or repressor (1). CDP and YY1 bind directly to the upstream region of the promoter in undifferentiated cells (1, 2). However, the detailed regulatory mechanism for the promoters in the HPV E7 ORF has yet to be fully elucidated.

A number of transcription factors that regulate cell differentiation have been found and grouped as the POU domain family (46). The POU domain is a DNA-binding domain originally identified in mammalian proteins Pit-1 (8, 27), Oct-1 (50), and Oct-2 (10) and in Caenorhabditis elegans protein unc-86 (13). Pit-1, Oct-2, and unc-86 induce terminal differentiation of pituitary cells, B lymphocytes, and neuronal cells, respectively. Skn-1a (4) (also referred to as Epoc-1 [56] or Oct-11 [17]), a member of the POU domain family, is primarily expressed in differentiating suprabasal keratinocytes but not in proliferating basal cells and plays important regulatory roles in both epidermal development and keratinocyte differentiation (5). Also, Skn-1a activates keratin 10 (4) and small proline-rich protein (14) genes and downregulates involucrin (52) and profilaggrin (28) genes through direct binding to their promoter regions, considered a trigger for epithelial differentiation (5). Murine Skn-1 and the recently isolated human Skn-1a (hSkn-1a) (22) have been shown to enhance transcription from promoters in the LCR of HPV types 1a, 16, and 18 (3, 22, 55).

In this study we have focused on the possible involvement of hSkn-1a in regulation of HPV16 P₆₇₀ and found that hSkn-1a activated expression of the luciferase gene driven by P₆₇₀, probably through direct binding to the promoter region in a sequence-specific manner. The binding sites were shared with YY1, and disruption of the sites raised the basal level of luciferase. YY1 in the YY1-DNA complex was displaced by hSkn-1a, strongly suggesting that the primary repression of P₆₇₀ by YY1 is abrogated by replacement of YY1 with hSkn-1a, which is expressed only in the differentiating keratinocytes.

	MATERIALS AND METHODS

Top Abstract Introduction Materials and Methods Results Discussion References

Construction of expression plasmids for hSkn-1a. The hSkn-1a cDNA in a human placenta cDNA library (Takara, Osaka, Japan) was amplified by PCR (advantage2 PCR kit; Clontech) using the sense primer (5'-AGG ATG GTG AAT CTG GAG TCC ATG CAC) and the antisense primer (5'-GTC TAC GTG GAG GTA GGT GGA ATG ATT). The DNA fragment was cloned into pGEM-T easy vector (Promega) to generate pGEM-T/hSkn-1a. The nucleotide sequence of the obtained cDNA was identical to that of the previously reported hSkn-1a cDNA (22). The DNA fragment encoding hSkn-1a was excised from pGEM-T/hSkn-1a by digestion with EcoRI, end blunted, and inserted into the pCMV4 expression plasmid (6) at the SmaI site, generating pCMV/hSkn-1a. The EcoRI fragment was also inserted in frame into pHM6 (Roche Molecular Biochemicals) at the EcoRI site to generate pHM/hSkn-1a, which expresses the N-terminal hemagglutinin (HA)-tagged hSkn-1a protein. The expression plasmid for Skn-1a with an N-terminal 187-amino-acid deletion (dN) was constructed by digestion of pHM/hSkn-1a with XhoI and self ligation. The DNA fragments encoding hSkn-1a with a C-terminal 92-amino-acid deletion (dC), both N- and C-terminal deletions (dN/dC), or POU domain deletion (dPOU) were synthesized by PCR (advantage-HF PCR kit; Clontech) using pGEM-T/hSkn-1a as a template. The sense primers were 5'-CGG AAT TCG ATG GTG AAT CTG GAG TCC for dC, 5'-CGG AAT TCC CTC GAG GAG CTG GAG AAG for dN/dC, and 5'-CGG AAT TCG ATG GTG AAT CTG GAG TCC for dPOU. The antisense primers were 5'-CGG AAT TCA GGC CAC AGG GCA GTT GAT for dC and dN/dC and 5'-CGG AAT TCA GTC ACT GGG CTC ATC GGC for dPOU. The primers were designed to have EcoRI sites at their 5' ends. The DNA fragments obtained by PCR were digested with EcoRI and inserted into pHM6 at the EcoRI site.

Construction of luciferase reporter plasmids. Construction of pLCR-Luc, which expresses the firefly luciferase gene under control of the HPV16 LCR, was described previously (33). To monitor transcription from P₆₇₀, p670-Luc was constructed by insertion of the DNA fragment carrying the luciferase gene in the place of the E1 gene. Luciferase DNA, which was synthesized by PCR using primers having NcoI sites at their 5' ends and digested with NcoI, was inserted at the NcoI site of the HPV16 PstI-B fragment in the pUC/LCR (33), pUC19 containing the 1776-bp PstI-B fragment. In the resultant plasmid, p670-Luc, an HPV16 DNA fragment from nucleotides (nt) 7010 through 7906 and from nt 1 to 864 was fused with the luciferase DNA at the first ATG codon of the E1 gene. Nucleotide substitutions were introduced into the TATA motif in the LCR or into the binding sites for hSkn-1a in pLCR-Luc or p670-Luc by using a Mutan-Super Express Km site-directed mutagenesis kit (Takara). The synthetic oligonucleotide used to abolish the TATA motif was 5'-AAA TGT CTG CTT TGA TGC TAA CCG GTT TC, and those to abrogate binding with hSkn-1a were 5'-CAG CTG TAA TCA AGG ACG GAG ATA CAC CTA (for binding site 1) and 5'-GAT ACA CCT ACA TAG GAC GAA TAT ATG TTA (for binding site 2). Nucleotides different from those of authentic sequences are underlined.

Cell culture and luciferase assays. HeLa S3 cells were grown in Dulbecco's modified Eagle medium supplemented with 10% fetal calf serum. In standard cotransfection assays, a mixture containing 200 ng of luciferase reporter plasmids, 200 ng of expression plasmids for hSkn-1a (or the backbone plasmid pCMV4), and 0.5 ng of a control plasmid containing the cytomegalovirus (CMV) promoter-driven Renilla luciferase was transfected into 40% confluent cells per well of a 24-well plate using the Effectene transfection reagent (Qiagen). At 48 h after transfection, luciferase activities of cellular extracts were measured by using the PicaGene Dual SeaPansy Luminescence Kit (Toyo Ink Co., Tokyo, Japan) and a microplate luminometer LB96V (Perkin Elmer Applied Biosystems). Efficiency of transfection was normalized using Renilla luciferase activity.

Immunoblotting. HeLa cells in a 10-cm-diameter dish were transfected with 2 µg of expression plasmids for hSkn-1a. Forty-eight hours later cells were washed twice with phosphate-buffered saline (PBS), resuspended in a sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) sample buffer, boiled for 5 min, and then subjected to SDS-12.5% PAGE. The resolved proteins were transferred electrophoretically onto Hybond-P membranes (Amersham Pharmacia Biotech, Uppsala, Sweden). The membranes were incubated with anti-Skn-1a antibody (Santa Cruz) (1:1,000) or anti-HA antibody (Roche Molecular Biochemicals) (1:10,000) in TBST (20 mM Tris [pH 7.5], 150 mM NaCl, and 0.1% Tween 20) containing 5% (wt/vol) skim milk for 1 h at room temperature, washed four times with TBST, incubated with horseradish peroxidase-conjugated anti-rabbit or anti-mouse antibody in TBST containing 5% skim milk for 1 h at room temperature, and then washed with TBST four times. Immunoreactive proteins were visualized by the ECL plus chemiluminescence detection system (Amersham Pharmacia Biotech).

Preparation of recombinant proteins. The hSkn-1a protein fused with glutathione S-transferase (GST-hSkn-1a) and the DNA-binding domain of human YY1 protein (amino acids 293 to 414) fused with GST (GST-YY1) (24) were bacterially produced. The EcoRI fragment isolated from pGEM-T/hSkn-1a was inserted in frame into the EcoRI site of pGEX-4T-3 (Amersham Pharmacia Biotech) to produce pGEX-4T-3/hSkn-1a. The DNA fragment encoding the YY1 DNA-binding domain was synthesized by PCR with a sense primer (5'-CGG AAT TCC AAG AAC AAT AGC TTG CCC), an antisense primer (5'-CGG AAT TCA CTG GTT GTT TTT GGC CTT), and a HeLa cell cDNA library. The PCR product was digested with EcoRI and cloned in frame into pGEX-2TK at the EcoRI site to produce pGEX-2TK/YY1. pGEX-4T-3/hSkn-1a and pGEX-2TK/YY1 were introduced into Escherichia coli strains BL21(DE3) plysS and JM109, respectively. The fusion proteins were purified by GSTrap affinity-column chromatography (Amersham Pharmacia Biotech) with AKTAprime (Amersham Pharmacia Biotech).

Electrophoretic mobility shift assay (EMSA). A mixture containing double-stranded ³²P-labeled oligonucleotides (0.4 pmol), either 1 µg of purified fusion proteins or 10 µg of total extracts from HeLa cells, 1 µg of poly(dI-dC) in a final volume of 10 µl of a buffer consisting of 20 mM Tris (pH 8.0), 50 mM NaCl, 10 mM MgCl₂, 10% glycerol, 1 mM dithiothreitol (DTT), 0.5 mM phenylmethylsulfonyl fluoride (PMSF), and 2 µg of aprotinin/ml was incubated at room temperature for 30 min. For supershift, anti-YY1 mouse monoclonal antibody (SC-7341; Santa Cruz Biotechnology, Inc., Santa Cruz, Calif.) (4 µg) was added to the reaction mixture. The sample was then loaded on a 5% polyacrylamide gel and electrophoresed in 0.5× Tris-borate-EDTA buffer at 4°C. Gels were dried and visualized by autoradiography on X-ray films.

Detection of HPV transcripts by 5' RACE and Southern blotting. The HPV16 genome, excised from pHPV16K (30) by digestion with BamHI and purified by extraction from an agarose gel after electrophoresis, was self ligated at concentrations of 50 ng/µl to avoid the formation of multimers. Using the Effectene transfection reagent, HeLa cells (10⁶ cells) were transfected with the circular HPV16 DNA (2 µg) with pCMV4 (2 µg) or pCMV/hSkn-1a (2 µg). At 48 h after transfection, mRNAs were extracted by using the QuickPrep mRNA Purification Kit (Amersham Pharmacia Biotech), followed by cDNA synthesis with the Marathon cDNA library kit (Clontech). cDNAs specific to HPV16 in the libraries were amplified by 5' rapid amplification of cDNA ends (RACE) (advantage2 PCR kit; Clontech) using 5' RACE adapter sense primer and antisense primer I (5'-ATC ATG TAT AGT TGT TTG CAG CTC TGT G, nt 178 to 151 of HPV16) or antisense primer II (5'-CAC TAC AGC CTC TAC ATA AAA CC, nt 939 to 917). PCR consisted of 5 cycles of denaturation at 94°C for 5 s and annealing/extension at 72°C for 2 min, 5 cycles of denaturation at 94°C for 5 s and annealing/extension at 70°C for 2 min, and 25 cycles of denaturation at 94°C for 5 s and annealing/extension at 68°C for 2 min. The PCR products were electrophoresed in a 0.7% agarose gel, transferred to Hybond-XL membranes (Amersham Pharmacia Biotech), and probed with ³²P-labeled oligonucleotides derived from HPV16 DNA, nt 7005 to 868 (the PstI fragment) or nt 628 to 868 (synthesized by PCR). Prehybridization and hybridization were done at 60°C for 1 h in ExpressHyb hybridization solution (Clontech) followed by washes in 2× SSC (1× SSC is 0.15 M NaCl plus 0.015 M sodium citrate)-0.05% SDS at room temperature and in 0.1× SSC-0.1% SDS at 50°C. The 5' RACE products were directly cloned into pGEM-T easy, and the clones containing HPV16 sequences were selected by standard colony hybridization with the probe of ³²P-labeled oligonucleotide derived from HPV16 nt 628 to 868. The cDNAs were sequenced with an ABI310 sequencer (Perkin-Elmer Applied Biosystems).

	RESULTS

Top Abstract Introduction Materials and Methods Results Discussion References

Activation of P₆₇₀ promoter by hSkn-1a. To examine expression from P₆₇₀, which drives E1 and late genes in HPV16 (18, 31), we constructed expression plasmids p670-Luc and, for comparison, pLCR-Luc (Fig. 1A). Plasmids pLCR-Luc and p670-Luc had a luciferase gene as a reporter in place of the E7 gene driven by P₉₇ and the E1 gene, respectively. For measurement of enhancing effects of hSkn-1a, HeLa cells were transfected with pLCR-Luc or p670-Luc together with the expression plasmid for hSkn-1a (pCMV/hSkn-1a) or its backbone plasmid, pCMV4. hSkn-1a expressed in HeLa cells transfected with pCMV/hSkn-1a or pHM/hSkn-1a was detected by immunoblotting using anti-hSkn-1a antibody, but endogenous hSkn-1a was undetectable in mock-transfected HeLa cells (data not shown). Forty-eight hours later, the luciferase activity was measured with the cellular lysates (Fig. 1A). As reported previously with murine Skn-1a (3, 55), hSkn-1a markedly enhanced luciferase expression from P₉₇ in pLCR-Luc. The luciferase expression with p670-Luc, although less efficiently than with pLCR-Luc, was also enhanced by hSkn-1a. It seems likely, from the following observations, that the expression of luciferase with p670-Luc, which contained the promoters P₉₇ and P₆₇₀ (Fig. 1A), was mainly directed by P₆₇₀.

View larger version (32K): [in this window] [in a new window]   FIG. 1.   Activation of HPV16 P670 by hSkn-1a. (A) Structures of the reporter plasmids are schematically illustrated on the left. HeLa cells were cotransfected with 0.2 µg of the luciferase reporter plasmids and 0.2 µg of pCMV4 or pCMV/hSkn-1a. Luciferase activities of cell extracts were measured at 48 h after transfection. Results are presented as means ± standard deviations of three independent experiments. (B) Effects of HPV16 E2 expression on the hSkn-1a-mediated activation of P670. HeLa cells were cotransfected with pCMV/hSkn-1a (1 µg), pLCR-Luc (0.2 µg) or p670-Luc (0.2 µg), and increasing amounts of pCMV/E2 (a gift from Peter M. Howley). Luciferase activities of cell extracts were measured at 48 h after transfection. Results are presented as means ± standard deviations of three independent experiments.

The POU domain of hSkn-1a capable of activating P₆₇₀. The POU domain, which acts as a DNA-binding motif and determines its binding specificity to target sequences (20), was sufficient to activate P₆₇₀. Plasmids were constructed for expression of N-terminal HA-tagged hSkn-1a (pHM/hSkn-1a) and its family of truncated proteins; the one with deletion of the N-terminal domain (pHM/dN), the one with deletion of the C-terminal domain (pHM/dC), the one with deletion of both domains (pHM/dNdC), and the one with deletion of the POU domain (pHM/dPOU) (Fig. 2A). Expression of the truncated proteins in HeLa cells transfected with these plasmids was shown by immunoblotting with anti-HA antibody (Fig. 2B). Capabilities of truncated hSkn-1a to activate transcription from P₆₇₀ were examined by measuring luciferase activities of lysate obtained from HeLa cells transfected with p670-Luc together with each of the pHM plasmids (Fig. 2C). The results showed that, like a full-size hSkn-1a, the POU domain alone (dN/dC) seems to be capable of transactivating P₆₇₀. The hSkn-1a lacking the POU domain did not transactivate P₆₇₀. Apparently, it remains to be investigated how the other domains, the C-terminal primary transactivation domain (22) and the N-terminal domain, which has been reported to exhibit either inhibitory or stimulatory effects on the transactivation by hSkn-1a (22), affect the activation of P₆₇₀.

View larger version (28K): [in this window] [in a new window]   FIG. 2.   hSkn-1a domains capable of transactivating P670. (A) Schematic representation of N-terminal HA-tagged truncated hSkn-1a expressed by pHM6 vector. (B) Immunoblotting detection of the truncated hSkn-1a in total extracts from HeLa cells transfected with pHM6 (a backbone plasmid) or expression plasmids for HA-tagged hSkn-1a with or without deletion. (C) Activation of P670 by the truncated hSkn-1a. HeLa cells were cotransfected with p670-Luc (0.2 µg) and 0.2 µg of the expression plasmids for HA-tagged hSkn-1a with or without deletion. Luciferase activities of cell extracts were measured at 48 h after transfection. Results are presented as means ± standard deviations of three independent experiments.

Binding of hSkn-1a to the upstream region of P₆₇₀. EMSAs showed that bacterially expressed and purified hSkn-1a fused with glutathione S-transferase (GST-hSkn-1a) bound to the synthetic double-stranded oligonucleotide probe having the sequence of HPV16 nt 7721 to 7750 (Fig. 3A and B). The nucleotide sequence from nt 7733 to 7738, TTGCAT, is similar to the previously described core sequence of mouse Skn-1a-binding sites in HPV18 LCR, TGCAT(A/C)T (55). Substitutions of A for T (nt 7733), G for C (nt 7735), and C for T (nt 7737) reduced binding of hSkn-1a with the probe. The results strongly suggest that hSkn-1a specifically binds to the HPV16 LCR sequence, which is similar to the mouse Skn-1a-binding site in HPV18 LCR (55).

View larger version (59K): [in this window] [in a new window]   FIG. 3.   Binding of hSkn-1a with synthetic oligonucleotides having partial sequences of the HPV16 E7 ORF. (A) Probes A through I used for EMSAs have nucleotide sequences of the regions schematically presented as rectangles. Numbers in parentheses indicate nucleotide numbers in HPV16 DNA (from the HPV Sequence Database of the Los Alamos National Laboratory). (B) EMSA detecting the complex of GST-Skn-1a with the 32P-labeled HPV16 probe. The DNA-protein complex was electrophoresed on a 5% polyacrylamide gel and visualized by autoradiography. (C) EMSA detecting the complex of GST-Skn-1a with the 32P-labeled probes having mutations in the putative hSkn-1a binding sites. TGCA(A/T) in probes C, E, and G were replaced with AGGAC to generate probes mC, mE, and mG, respectively. (D) Cross-competition in an EMSA. Complex formed GST-hSkn-1a, and a mixture of 32P-labeled probes (0.4 pmol) and 4 pmol (×10) or 20 pmol (×50) of unlabeled competitors was electrophoresed on a 5% polyacrylamide gel and visualized by autoradiography. (E) EMSA detecting the complex of Skn-1a expressed in HeLa cells and probe E. Total extracts from HeLa cells transfected with the expression plasmids for HA-tagged hSkn-1a with or without deletion was allowed to form a complex with 32P-labeled probe E.

View larger version (42K): [in this window] [in a new window]   FIG. 4.   Nucleotide sequence upstream of P670. The putative hSkn-1a binding sites 1, 2, and 3 are underlined. Boxed in gray is CAT, which may serve as a core of YY1-binding sites. The sequence is from the Los Alamos National Laboratory database.

Binding of YY1 to the upstream region of P₆₇₀. YY1, a potential transcriptional repressor, was examined for its ability to bind to the upstream region of HPV16 P₆₇₀, because a recent study of HPV6 (1) suggests that it may negatively regulate expression from P₆₇₀. For binding assays, fusion protein GST-YY1 was used, which is comprised of the DNA-binding domain of human YY1 protein (amino acids 293 to 414) and GST. GST-YY1 was found to form a complex with the ³²P-labeled YY1-wt, an oligonucleotide probe containing the consensus YY1-binding motif (19), but not with YY1-mut, the probe having a mutation in the motif in EMSA (Fig. 5A). Because DNA-binding properties of YY1 and full-length YY1 have been shown to be indistinguishable (23), the EMSA data using GST-YY1 is considered to reflect the behavior of native YY1 in complex formation.

View larger version (46K): [in this window] [in a new window]   FIG. 5.   Binding of YY1 with synthetic oligonucleotides having partial sequences of the HPV16 E7 ORF. (A) EMSA detecting the complex of GST-YY1 with 32P-labeled probe having sequences with which YY1 has been shown to bind (YY1-wt) or not to bind (YY1-mut) (19) (left panel) and the complex of GST-YY1 with the 32P-labeled HPV16 probes (see Fig. 3A) (right panel). The DNA-protein complexes were electrophoresed on a 5% polyacrylamide gel and visualized by autoradiography. (B) EMSA detecting the complex of GST-YY1 with the 32P-labeled probes having mutations in the putative hSkn-1a binding sites (see the legend to Fig. 3C). (C) EMSA showing displacement of YY1 from the complex of YY1/probe C by Skn-1a. The mixture of GST-YY1 and 32P-labeled probe C or 32P-labeled probe YY1-wt was incubated (inc.) for 30 min. Then GST-Skn-1a was added to the mixture, and the mixture was further incubated for 5 min. The DNA-protein complexes were electrophoresed on a 5% polyacrylamide gel and visualized by autoradiography. Closed and open triangles indicate complexes of GST-YY1/probe C and GST-Skn-1a/probe C, respectively. (D) EMSA detecting the complex of HeLa cell YY1 and 32P-labeled probes. The HeLa extract containing endogenous YY1 was mixed with the probe indicated (see the legends to Fig. 3A and 5A), and the mixture was incubated. The DNA-protein complexes were separated by electrophoresis on a 5% polyacrylamide gel and visualized by autoradiography. To detect the presence of YY1 in the complex, anti-YY1 mouse monoclonal antibody (-YY1) or purified mouse immunoglobulin G was added to the reaction mixture to show the supershift of the migrating bands. Closed and hatched triangles indicate the complexes of YY1/probe and the YY1/anti-YY1 antibody/probe, respectively. Ab, antibody.

Expression of luciferase with p670-Luc having mutations in hSkn-1a/YY1 binding sites 1 and 2. When the nucleotide substitutions that abolished bindings of hSkn-1a and YY1 to probes C and E in EMSAs (Fig. 3C and 5B) were introduced into corresponding regions of mTATA/p670-Luc to abolish bindings with YY1 and hSkn-1a, the basal level of the luciferase expression from P₆₇₀ without hSkn-1a was raised and the effects of mutations in the two sites were synergistic. Luciferase activities of HeLa cells transfected with mTATA/m1/p670-Luc and mTATA/m2/p670-Luc, which had the mutations in hSkn-1a-binding sites 1 and 2, respectively, were elevated to nearly half of the activities obtained by the activation by hSkn-1a (Fig. 6). Luciferase activity of HeLa cells transfected with mTATA/m1&m2/p670-Luc, of which the two sites were mutated, was higher than those obtained with mTATA/m1/p670-Luc or mTATA/m2/p670-Luc, and the activation by hSkn-1a was no longer prominent. The results indicate that transcription from P₆₇₀ is primarily suppressed by YY1.

View larger version (22K): [in this window] [in a new window]   FIG. 6.   Activation of P670 by disruption of the hSkn-1a/YY1-binding sites. The nucleotide substitutions (see the legend to Fig. 3C) were introduced in sites 1 and 2 in mTATA/p670-Luc to generate plasmids lacking binding sites for hSkn-1a/YY1. HeLa cells were cotransfected with 0.2 µg of the plasmids with the mutations and 0.2 µg of pCMV4 or pCMV/Skn-1a. Luciferase activities of cell extracts were measured at 48 h after transfection. Results are presented as means ± standard deviations of three independent experiments.

Effect of hSkn-1a on transcription from P₆₇₀ of HPV16 DNA. Expression of hSkn-1a resulted in activation of transcription from P₆₇₀ in HPV16 DNA to produce mRNA encoding the E1 protein (Fig. 7). To analyze the effect of hSkn-1a on authentic transcription from HPV16 DNA, HeLa cells were transfected with a complete circular genome of HPV16 together with pCMV/hSkn-1a or with pCMV4. At 48 h after transfection, mRNA was isolated by oligo(dT) column chromatography, followed by cDNA synthesis. HPV16-specific transcripts were amplified by 5' RACE using two HPV16-specific primers; primer I anneals the E6 region and primer II anneals the E1 region, which is not present in E1E4 mRNA generated by the splicing. The amplified DNA fragments were electrophoresed on an agarose gel, followed by Southern blotting using two radiolabeled probes hybridizing the HPV16 region of nt 7005 to 868 or nt 628 to 868 (Fig. 7A). 5' RACE with primer I similarly amplified cDNAs derived from transcripts from P₉₇ with or without hSkn-1a (Fig. 7B). The enhancing effect of hSkn-1a on transcription from P₉₇ may be interfered with by E2 protein in a negative-feedback manner. 5' RACE with primer II amplified cDNA of around 300 bp in the cDNA library constructed from HeLa cells expressing hSkn-1a (Fig. 7C). Without hSkn-1a, the cDNA was not synthesized. The cDNA molecules were cloned into pGEM-T easy plasmid and were sequenced. The 5' ends of cDNAs were near at nt 670, and the most 5'-upstream nucleotide of cDNAs sequenced was G at nt 694. The function of transiently expressed hSkn-1a was verified by induction of synthesis of keratin 10 mRNA in HeLa cells transfected with pCMV/hSkn-1a (Fig. 7D). Thus, the results obtained in the experiments using expression plasmids for luciferase driven by P₆₇₀ seem to mimic expression of the E1 gene in HPV16 infection.

View larger version (21K): [in this window] [in a new window]   FIG. 7.   Transcription from circular HPV16 DNA in HeLa cells expressing hSkn-1a. (A) Schematic representation of the gene organization of HPV16 and transcripts from P97 and P670. I and II are primers used to amplify cDNAs derived from HPV16 transcripts by 5' RACE. (B) The cDNAs were amplified by 5' RACE using the primer I and cDNA libraries constructed from HeLa cells transfected with pCMV4 (the backbone plasmid) (lane 1) or pCMV/hSkn-1a (lane 2). The PCR products were electrophoresed in a 0.7% agarose gel, transferred to nylon membranes, and probed with 32P-labeled oligonucleotides derived from the indicated region of HPV16 DNA. cDNAs hybridized with the probes were visualized by autoradiography. (C) Experiments were carried out as described for panel B except that primer II was used for 5' RACE. (D) PCR-amplified cDNAs of human keratin 10 and human -actin in cDNA libraries constructed from HeLa cells transfected with pCMV4 (lane 1) or with pCMV/hSkn-1a (lane 2). The cDNA corresponding to the region from exons 2 to 4 of human keratin 10 (44) was amplified using the sense primer 5'-CTAACAACTGAT AATGCCAACATCCTG and the antisense primer 5'-GGGGCA GCATTCATTTCCACATTCACA. Part of the -actin cDNA was amplified using the primer set of TaqMan -actin Control Reagent (Perkin Elmer Applied Biosystems). The PCR products were electrophoresed on a 1.2% agarose gel, followed by staining with ethidium bromide. The sequences of the cDNAs agreed with those in the database (GenBank).

	DISCUSSION

Top Abstract Introduction Materials and Methods Results Discussion References

This study has shown that the POU transcription factor hSkn-1a, which is known to modulate the expression of several genes associated with keratinocyte differentiation (4, 5), activates HPV16 P₆₇₀ on the expression plasmid and the circular HPV16 DNA in the transient expression assays and that the upstream promoter region contains two specific binding sites for hSkn-la, which are shared by YY1, a transcriptional regulator. The results indicate that hSkn-la is probably capable of activating transcription from P₆₇₀ by binding to DNA in a sequence-specific manner in natural HPV16 infection. Transcripts from promoters in the E7 ORF, such as P₆₇₀ and P₇₄₂ of HPV31, encode helicase (E1) and capsid proteins (L1 and L2) (25, 31, 38). Replication of the HPV genome and accumulation of HPV capsid proteins have been observed in the suprabasal differentiating strata (45), where hSkn-1a is predominantly expressed (4, 5). Thus, hSkn-1a, by activating P₆₇₀, is likely to initiate HPV16 vegetative replication leading to virion production in differentiating keratinocytes.

Human Skn-1a seems to activate P₆₇₀ by displacing YY1 bound to the two sites for hSkn-1a. The displacement was shown to occur in vitro in this study (Fig. 5C). Because YY1 is abundant in most cells (47, 51) and is a probable transcriptional repressor in the HPV6 replication (1), it would be reasonable to presume that YY1 in HeLa cells or undifferentiated keratinocytes readily binds to the viral hSkn-1a-binding sites, resulting in repression of P₆₇₀ on the transfecting expression plasmid or persisting episomal HPV16 DNA (16, 36, 42, 48, 53). In fact, the expression from P₆₇₀ was enhanced greatly when YY1 was prevented from binding to the promoter region modified by the substitution mutations (Fig. 6). It is probable, therefore, that hSkn-1a emerging in differentiating keratinocytes removes YY1 bound to the hSkn-1a sites in the promoter region on episomal HPV16 DNA and initiate virion production.

The results of substitution analyses (Fig. 6) also suggest that the activation of P₆₇₀ by hSkn-1a depends mostly on the removal of YY1 but not on the potential activator function of hSkn-1a, because when the binding sites were disrupted by nucleotide substitutions, the basal level of expression from P₆₇₀ was comparable to that brought about by hSkn-1a-mediated activation. The results are consistent with the fact that the POU domain alone was sufficient to activate the expression as efficiently as the full-length hSkn-1a (Fig. 2).

The putative binding sequence for hSkn-1a, (A/T)TGCA(A/T)XX, found in this study with HPV16 was searched for in the homologous promoter regions of various HPVs (of the HPV Sequence Database of the Los Alamos National Laboratory). The sequence was found in HPV types 6 (11), 18, 31, and 45 but not in types 1, 5, 8, 33, 52, and 58. It remains to be investigated whether hSkn-1a can bind to a different motif or whether a yet unidentified factor(s) other than hSkn-1a can initiate HPV replication in the differentiating cells.

It would be of interest to know whether other keratinocyte-specific transcription factors can activate HPV promoters. Besides Skn-1a, the epidermis contains other POU domain transcription factors, such as Tst-1, Oct-1, and Oct-2 (5). The expression of Tst-1 is also linked to keratinocyte differentiation (12), whereas the ubiquitous factor Oct-1 is expressed independently of the differentiation and Oct-2 is expressed only in undifferentiated keratinocytes. Since Skn-1a and Tst-1 appear to function redundantly in keratinocyte differentiation in mice (5), it is possible that Tst-1 is capable of activating HPV promoters. Understanding the transcriptional regulation of HPVs in differentiating keratinocytes would help develop a cell culture system that allows HPVs to grow efficiently in vitro.